Chromocell Therapeutics Corporation (CHRO)
- Previous Close
1.5000 - Open
1.4899 - Bid 1.5500 x 1000
- Ask 1.7500 x 1400
- Day's Range
1.4799 - 1.7800 - 52 Week Range
1.2100 - 6.0000 - Volume
26,703 - Avg. Volume
33,632 - Market Cap (intraday)
9.405M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the development and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain and acute and chronic eye pain. Chromocell Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey.
www.chromocell.comRecent News: CHRO
Compare To: CHRO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CHRO
Valuation Measures
Market Cap
9.40M
Enterprise Value
10.58M
Trailing P/E
121.67
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-1.54
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-5,663.30%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-7.38M
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
96.39k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-640.57k